Dr. Howard Smith Oncall

Vidcast:  https://www.instagram.com/drhowardsmithreports/reel/DEnbKUyPVnE/ Atogepant is an oral CGRP receptor antagonist, that is a calcitonin gene-related peptide receptor antagonist, that works exceptionally fast.  New York’s Albert Einstein College of Medicine now report a meta-analysis of 3 clinical trials involving 1243 people with episodic and chronic migraines.  The studies revealed that atogepant reduced the incidence of migraine on the first day of therapy by as much as 50%.  Those taking the drug reported fewer days with migraines over time and an improved quality of life. The 3 studies enrolled predominately white, female participants and must be repeated with a more diverse subject population.  Assuming confirmation of these findings, atogepant may offer rapid and welcome migraine relief. https://www.neurology.org/doi/10.1212/WNL.0000000000210212 #migraine #atogepant #cgrp